

BBS-Bioactive Bone Substitutes Plc: Financial calendar and Bankruptcy

BBS-Bioactive Bone Substitutes Plc | Company Release | February 20, 2025 at 21:00:00 EET

BBS-Bioactive Bone Substitutes Plc: Financial calendar and Bankruptcy

Due to the bankruptcy, BBS-Bioactive Bone Substitutes Plc ("BBS") will not publish the previously announced financial statement release for the year 2024. The bankruptcy estate will also not publish a statement.

BBS will not issue other statements mentioned in the previous announcement due to the bankruptcy.

For more information, please contact: Attorney Valtteri Vuorenmaa <u>valtteri.vuorenmaa@fennolaw.fi</u> +358 50 350 2123

Certified Advisor: Nordic Certified Adviser AB, +46 70 551 67 29, info@certifiedadviser.se

Distribution Nasdaq Helsinki https://www.bbs-artebone.fi/

BBS in brief

BBS-Bioactive Bone Substitutes Plc is an orthobiology company that started its operations in 2003. We have developed a new product for the treatment of complex bone fractures and bone healing issues. Our goal is to provide next-generation medical products for the treatment of bone injuries in orthopedic surgery. In the pharmaceutical industry, the development and research work require perseverance and courage to innovate. We have a track record of over 20 years in this field. Our company is characterized by expertise, innovation, and dedicated employees who are passionate about their work. Our first developed product, ARTEBONE® Paste, is in the final stages of the CE marking process to enable its commercialization in the EU market. We are based in Oulu with a medical manufacturing facility in Reisjärvi, holding a manufacturing license. The company's headquarters are in Oulu, and we employ over 20 people.

BBS has been listed on Nasdaq First North Growth Market Finland since February 2018.

More information: www.bbs-artebone.fi